cyanidin has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arjsri, P; Dejkriengkraikul, P; Mapoung, S; Semmarath, W; Srisawad, K; Thippraphan, P; Umsumarng, S; Yodkeeree, S | 1 |
| Barquero, AA; Benedetti, M; Bueno, CA; Gentilini, MV; Martelliti, P; Nabaes Jodar, MS; Peñaranda Figueredo, FA; Vázquez, L; Vicente, J; Viegas, M | 1 |
2 other study(ies) available for cyanidin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Cyanidin-3-O-glucoside and Peonidin-3-O-glucoside-Rich Fraction of Black Rice Germ and Bran Suppresses Inflammatory Responses from SARS-CoV-2 Spike Glycoprotein S1-Induction In Vitro in A549 Lung Cells and THP-1 Macrophages via Inhibition of the NLRP3 Inf
Topics: Anthocyanins; COVID-19; Glucosides; Humans; Inflammasomes; Interleukin-18; Lung; Macrophages; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Oryza; Post-Acute COVID-19 Syndrome; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2022 |
The Flavonoid Cyanidin Shows Immunomodulatory and Broad-Spectrum Antiviral Properties, Including SARS-CoV-2.
Topics: Animals; Antiviral Agents; COVID-19; Flavonoids; Interleukin-17; Mice; NF-kappa B; SARS-CoV-2 | 2023 |